Article
Public, Environmental & Occupational Health
Leyuan Liu, Xiaoxiao Wang, Xiaoguang Li, Nan Li
Summary: The study shows that COVID-19 vaccination can reduce public anxiety and promote willingness for future antibody testing, with those experiencing higher levels of anxiety more likely to undergo antibody testing.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Pharmacology & Pharmacy
Ophelia Yin, Yuan Xiong, Seiko Endo, Kazutaka Yoshihara, Tushar Garimella, Malaz AbuTarif, Russ Wada, Frank LaCreta
Summary: This study characterized the pharmacokinetics of Trastuzumab deruxtecan in patients with HER2-positive breast cancer or other solid tumor malignancies. Results showed no significant differences in steady-state exposure of the drug in different patient populations, suggesting that dose adjustment based on specific patient characteristics is not necessary.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Oncology
Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah, Salaheldin S. Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K. Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F. Pierce, Nam Atiqur Rahman, Shenghui Tang, Bronwyn D. Mixter, Paul G. Kluetz, Richard Pazdur, Laleh Amiri-Kordestani
Summary: On November 14, 2022, the FDA granted accelerated approval for mirvetuximab soravtansine-gynx in the treatment of a specific type of ovarian cancer. This targeted therapy is the first of its kind for this particular type of cancer and the first antibody-drug conjugate approved for ovarian cancer.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Alma Lucia Villela Zumaya, Silvie Rimpelova, Marketa Stejdirova, Pavel Ulbrich, Jarmila Vilcakova, Fatima Hassouna
Summary: In this study, anti-CD133 monoclonal antibody-conjugated PLGA nanocarriers were designed and synthesized for targeted delivery of oxaliplatin and superparamagnetic nanoparticles to colorectal cancer cells. The results showed that non-PEGylated PLGA nanoparticles were more convenient for controlled drug release, while PEGylated PLGA nanoparticles had faster release kinetics. Additionally, the nanoparticles exhibited superparamagnetic behavior without magnetic hysteresis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Summary: Triple-positive breast tumors overexpress HER2 and are positive for HR expression. ER expression affects the response to anti-HER2 and associated systemic therapies. Optimizing dual anti-HER2 blockade is important for disease control in triple-positive tumors.
CANCER TREATMENT REVIEWS
(2023)
Article
Engineering, Biomedical
Kwang Suk Lim, Daniel Y. Lee, Seungmin Han, David A. Bull, Young-Wook Won
Summary: HSP90 is crucial for cancer cell survival, and incorporating HSP90 inhibitors into antibodies through biological affinity binding can enhance targeted delivery and improve anti-cancer efficacy.
Article
Biochemistry & Molecular Biology
Aleksandra Rodak, Katharina Stadlbauer, Madhusudhan Reddy Bobbili, Oskar Smrzka, Florian Rueker, Gordana Wozniak Knopp
Summary: This study developed an antibody-drug conjugate that showed cytotoxicity for IgE-positive cells. The antibody had fast internalization and strict target specificity, providing a valuable starting point for the development of an anti-IgE cell-depleting agent.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Allergy
Margaret M. Kuder, John C. McDonnell, Katherine Weller, Manshi Li, Xiafeng Wang, David M. Lang
Summary: This study reassessed the proportion of patients with positive penicillin skin tests and vague or low-risk reaction histories, and evaluated the relationship between reaction risk history and the likelihood of positive skin test results. The study found that a substantial proportion of patients who self-reported penicillin allergy and had positive skin test results had a low-risk history, and that penicillin skin testing was associated with a poor positive predictive value.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Article
Chemistry, Multidisciplinary
Seol Hwa Shin, Yun-Hee Park, Seok Soon Park, Eun Jin Ju, Jin Park, Eun Jeong Ko, Dong Jun Bae, Sang-Yeob Kim, Chul-Woong Chung, Ho Young Song, Se Jin Jang, Seong-Yun Jeong, Si Yeol Song, Eun Kyung Choi
Summary: LCB-ADC exhibits higher cytotoxicity compared to T-DM1 and effectively inhibits tumor growth in animal models with HER2 high expression. Furthermore, LCB-ADC demonstrates good efficacy in suppressing tumor growth in HER2-positive gastric cancer PDX model and T-DM1-resistant models.
Article
Biochemistry & Molecular Biology
Jan Olof G. Karlsson, Per Jynge, Louis J. Ignarro
Summary: The highly negative results from the POLAR A and M phase III trials in patients with colorectal cancer, treated with an oxaliplatin-based regimen and co-treated with calmangafodipir, revealed a significant increase in chemotherapy-induced peripheral neuropathy in patients treated with PledOx compared to placebo. The etiology of this increase in side effects remains unclear, but it is potentially due to unfavorable redox interactions between PledOx and oxaliplatin caused by the timing of administration.
Review
Medicine, General & Internal
Lixi Li, Di Zhang, Binliang Liu, Dan Lv, Jingtong Zhai, Xiuwen Guan, Zongbi Yi, Fei Ma
Summary: Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs, and have shown potential as a promising treatment option for breast cancer and other tumors.
CHINESE MEDICAL JOURNAL
(2022)
Article
Medicine, Research & Experimental
Keisuke Kiyomiya, Ryuto Tomabechi, Naoki Saito, Kenta Watai, Tappei Takada, Yoshiyuki Shirasaka, Hisanao Kishimoto, Kei Higuchi, Katsuhisa Inoue
Summary: Macrolide and ketolide antibiotics can attenuate the cytotoxicity of HER2-targeting antibody-drug conjugate T-DM1 by accumulating in the lysosomes and inhibiting the function of SLC46A3, resulting in potential drug-ADC interaction during cancer chemotherapy.
MOLECULAR PHARMACEUTICS
(2023)
Article
Biochemical Research Methods
Ludovic Juen, Christine B. Baltus, Camille Gely, Ofelia Feuillatre, Audrey Desgranges, Marie-Claude Viaud-Massuard, Camille Martin
Summary: The McSAF Inside technology, based on a trifunctionalized di(bromomethyl)pyridine scaffold, allows for the conjugation of a linker-payload to previously reduced interchain cysteines of a native antibody, resulting in highly stable and homogeneous ADCs with controlled drug-to-antibody ratio (DAR) and linker-payload position. The resulting ADC, MF-BTX-MMAE, showed improved DAR homogeneity, reproducibility, and stability compared to Adcetris in a CD30-positive lymphoma model, demonstrating similar antigen-binding, cytotoxicity, efficacy, and tolerability. The technology provides access to relevant ADCs with improved characteristics and stability, fulfilling current regulatory expectations for new ADC development.
BIOCONJUGATE CHEMISTRY
(2021)
Review
Urology & Nephrology
Yong Wu, Yuanjun Wu, Ganping Guo, Jiajun Zeng, Yan Liu, Yueqin Wu
Summary: This study provides a comprehensive description of the serological features and course of a patient with hypertensive nephropathy who developed drug-induced immune hemolytic anemia during repeated administration of piperacillin-tazobactam. The serological tests confirmed the diagnosis of piperacillin-induced immune hemolytic anemia. This study is important for deepening the understanding of drug-induced immune hemolytic anemia and learning from it.
Review
Oncology
G. Antonarelli, C. Corti, B. T. Salimbeni, P. Tarantino, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Summary: The introduction of antibody-drug conjugates (ADCs) has greatly impacted the treatment of patients with HER2-positive advanced breast cancer (ABC) in the past decade. ADCs have the ability to deliver toxic chemotherapeutics to tumor sites by utilizing monoclonal antibodies. Two different ADCs, trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have already been used in clinical practice for HER2-positive ABC treatment, with T-DXd showing better survival outcomes. However, there is still a clinical controversy regarding treatment decisions and benefits following T-DXd. The field of breast cancer research is rapidly changing with the development of novel ADC formulations, and addressing T-DXd resistance is a priority.
